Pharmaceuticals firm Biological E today said it has reduced the price of its COVID-19 vaccine Corbevax to ₹ 250 from ₹ 840 a dose, inclusive of goods and services tax, for private vaccination centres.
It would result in end-users paying ₹ 400 a dose, including taxes and administration charges, the company said in a statement.
Previously, in private vaccination centres the overall cost to end-users of the vaccine was ₹ 990 a dose, including taxes and administration charges, it added.
In March this year when the inoculation of children in the age group of 12 to 14 years started in India, Corbevax vaccine was used and its price was fixed at ₹ 145 for the government’s vaccination programme.
“BE has lowered the price of its vaccine with the aim of making it more affordable and help increase the reach to protect the maximum number of children against the virus,” the company said.
In April, the drugs regulator had granted Emergency Use Authorisation for Biological E’s Corbevax for children in 5 to 12 years group along with Bharat Biotech’s Covaxin for children in the age group of 6 to 12 years.
BE had collaborated with Texas Children’s Hospital and Baylor College of Medicine in the development of Corbevax. Prior to receiving EUA for vaccination, the company said it conducted phase II and III multi-centre clinical trials in 624 children aged 5-12 and 12-18.